IL23A and psoriasis: Risankizumab is a humanized IgG1 monoclonal antibody that is able to target the p19 subunit on the IL-23 (Horst and Cross, 2023; Sakkas et al., 2019) and has proven efficacy in psoriasis, psoriatic arthritis and CD (Baeten et al., 2018).